The addition of the immunomodulator mifamurtide to adjuvant chemotherapy for early osteosarcoma: a retrospective analysis
Conclusions. Mifamurtide was well tolerated in a Greek osteosarcoma population, including patients older than 30 years. The small sample size and the non-comparative design do not allow drawing conclusions on the drug benefit in terms of survival.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Bone Cancers | Chemotherapy | Drugs & Pharmacology | Greece Health | Investigational New Drugs | Methotrexate | Osteosarcoma | Pericarditis | Sarcomas | Study